ID29876A - Komposisi yang mengandung asam difosfonat - Google Patents

Komposisi yang mengandung asam difosfonat

Info

Publication number
ID29876A
ID29876A IDW20010789A ID20010789A ID29876A ID 29876 A ID29876 A ID 29876A ID W20010789 A IDW20010789 A ID W20010789A ID 20010789 A ID20010789 A ID 20010789A ID 29876 A ID29876 A ID 29876A
Authority
ID
Indonesia
Prior art keywords
diphosphonate
acids
contain
composition
diphosphonate acids
Prior art date
Application number
IDW20010789A
Other languages
English (en)
Indonesian (id)
Inventor
Rolf-Dieter Gabel
Walter Preis
Heinrich Woog
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29876(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ID29876A publication Critical patent/ID29876A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20010789A 1998-10-09 1999-10-01 Komposisi yang mengandung asam difosfonat ID29876A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119102A EP0998932A1 (de) 1998-10-09 1998-10-09 Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ID29876A true ID29876A (id) 2001-10-18

Family

ID=8232769

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010789A ID29876A (id) 1998-10-09 1999-10-01 Komposisi yang mengandung asam difosfonat

Country Status (35)

Country Link
US (2) US6294196B1 (pl)
EP (2) EP0998932A1 (pl)
JP (2) JP4471498B2 (pl)
KR (1) KR100522505B1 (pl)
CN (1) CN1150000C (pl)
AR (3) AR014081A1 (pl)
AT (1) ATE311887T1 (pl)
AU (1) AU752532B2 (pl)
BR (1) BR9914367A (pl)
CA (1) CA2346662C (pl)
CO (1) CO5050325A1 (pl)
CY (1) CY1105437T1 (pl)
CZ (1) CZ299008B6 (pl)
DE (1) DE69928819T2 (pl)
DK (1) DK1117412T3 (pl)
ES (1) ES2253919T3 (pl)
HK (1) HK1040914B (pl)
HR (1) HRP20010243B1 (pl)
HU (1) HU226457B1 (pl)
ID (1) ID29876A (pl)
IL (3) IL141912A0 (pl)
MA (1) MA27123A1 (pl)
ME (1) ME00637B (pl)
MY (1) MY126625A (pl)
NO (1) NO327447B1 (pl)
NZ (1) NZ510433A (pl)
PE (1) PE20001082A1 (pl)
PL (1) PL194552B1 (pl)
RS (1) RS49809B (pl)
RU (1) RU2207860C2 (pl)
SI (1) SI1117412T1 (pl)
TR (1) TR200100889T2 (pl)
TW (1) TW576742B (pl)
WO (1) WO2000021540A1 (pl)
ZA (1) ZA200102276B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
NZ552514A (en) * 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
AU2006222690B2 (en) * 2002-12-20 2009-04-23 F. Hoffmann-La Roche Ag High dose ibandronate formulation
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JPWO2005072746A1 (ja) * 2004-01-30 2007-10-11 アステラス製薬株式会社 P2x受容体阻害剤
DE602005025977D1 (de) * 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
KR100908529B1 (ko) * 2005-02-01 2009-07-20 에프. 호프만-라 로슈 아게 이반드로네이트 다형체 에이
JP5828607B2 (ja) * 2005-02-01 2015-12-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft イバンドロネート多形b
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US20100120723A1 (en) * 2006-12-20 2010-05-13 Mostafa Akbarieh Pharmaceutical composition comprising a hot-melt granulated lubricant
ES2623328T3 (es) * 2009-09-18 2017-07-11 Sitec Pharmabio Sl Procedimiento para la deshidratación de productos en polvo
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
EP2661262B1 (en) 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
DE3767998D1 (de) * 1986-12-20 1991-03-14 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
AU661080B2 (en) 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
AU1193092A (en) 1992-01-10 1993-08-03 Obschestvo S Ogranichennoi Otvetstvennostju Meditsinsky Nauchno-Proizvodstvenny Komplex Biotiki Granulated pharmaceutical composition and method of obtaining it
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4228552A1 (de) 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
BR9307859A (pt) 1993-05-15 1996-01-09 Boehringer Mannheim Gmbh Comprimido com biodisponibilidade aperfeiçoada que contérn ácido
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation

Also Published As

Publication number Publication date
KR100522505B1 (ko) 2005-10-18
AU752532B2 (en) 2002-09-19
IL141912A (en) 2006-12-10
RU2207860C2 (ru) 2003-07-10
MY126625A (en) 2006-10-31
AR047815A2 (es) 2006-02-22
AR069942A2 (es) 2010-03-03
ATE311887T1 (de) 2005-12-15
WO2000021540A1 (en) 2000-04-20
CO5050325A1 (es) 2001-06-27
PE20001082A1 (es) 2000-10-18
CZ20011233A3 (cs) 2001-09-12
PL347243A1 (en) 2002-03-25
EP1117412B1 (en) 2005-12-07
ME00637B (me) 2008-08-07
JP4471498B2 (ja) 2010-06-02
US20020006441A1 (en) 2002-01-17
CZ299008B6 (cs) 2008-04-02
HUP0103931A3 (en) 2003-01-28
EP1117412A1 (en) 2001-07-25
HU226457B1 (en) 2008-12-29
MA27123A1 (fr) 2005-01-03
NO20011714D0 (no) 2001-04-05
CN1319015A (zh) 2001-10-24
ES2253919T3 (es) 2006-06-01
NO327447B1 (no) 2009-06-29
DK1117412T3 (da) 2006-04-03
TW576742B (en) 2004-02-21
DE69928819D1 (de) 2006-01-12
HUP0103931A2 (en) 2002-06-29
US6627221B2 (en) 2003-09-30
HRP20010243A2 (en) 2002-04-30
HK1040914B (zh) 2004-12-10
HRP20010243B1 (hr) 2011-02-28
CN1150000C (zh) 2004-05-19
EP0998932A1 (de) 2000-05-10
CA2346662C (en) 2006-05-09
KR20010073203A (ko) 2001-07-31
ZA200102276B (en) 2002-06-19
NO20011714L (no) 2001-04-05
RS49809B (sr) 2008-08-07
AU6467599A (en) 2000-05-01
HK1040914A1 (en) 2002-06-28
AR014081A1 (es) 2001-01-31
SI1117412T1 (sl) 2006-04-30
IL177940A (en) 2012-05-31
IL141912A0 (en) 2002-03-10
BR9914367A (pt) 2001-06-26
YU20501A (sh) 2003-02-28
PL194552B1 (pl) 2007-06-29
DE69928819T2 (de) 2006-07-20
JP2002527398A (ja) 2002-08-27
TR200100889T2 (tr) 2001-07-23
CA2346662A1 (en) 2000-04-20
US6294196B1 (en) 2001-09-25
IL177940A0 (en) 2006-12-31
JP2010116408A (ja) 2010-05-27
CY1105437T1 (el) 2010-04-28
NZ510433A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
DE69905371D1 (de) Härtbare zusammensetzung
ID22095A (id) Asam aril-akrilat ester
DE69824961D1 (de) Härtbare zusammensetzung
ID26222A (id) Hidroksamida asam(4-arilsulfonilamino)-tetrahidropiran-4-karboksilat
ID28833A (id) Turunan asam 3-aril-2-hidroksipropionat
ID26186A (id) Komposisi sampo
ID18145A (id) Asam fosfinik amida sebagai inhibitor metaloprotease matriks
ID20481A (id) Komposisi-komposisi yang mengandung asam-asam hidroksi atau retinoid
DE69925322D1 (de) Polymerisierbare Zusammensetzung
ID26926A (id) Komposisi shampo pembentuk mode
ATE351896T1 (de) Brennstoffzusammensetzung
ID28329A (id) Komposisi-komposisi yang sesuai untuk sel-sel elektrokimia
ID23668A (id) Turunan asam ariloksiarilsulfonilamino hidroksamat
ID20807A (id) Asam sulfonilaminokarboksilat
ID20809A (id) Asam diaminokarboksilat tersubstitusi
CZ20011233A3 (cs) Kompozice obsahující difosfonové kyseliny
ID25508A (id) Komposisi dematologis
DE69908507D1 (de) Zusammensetzung zur Bekämpfung von schädlichen Arthropoden
DE69928862D1 (de) Zusammensetzung
DE69832067D1 (de) Farbzusammensetzung
DE69821948D1 (de) Härtbare zusammensetzung
ID23250A (id) Komposisi paroksetin
ID21906A (id) Komposisi adesif
ID28810A (id) Senyawa-senyawa amida-omega asam n-arilsulfonilamino
DE69918180D1 (de) Kathodische elektrotauchlackzusammensetzung